SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+7.96%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.32B
AUM Growth
+$1.32B
(+9.9%)
Cap. Flow
+$196M
Cap. Flow
% of AUM
14.83%
Top 10 Holdings %
Top 10 Hldgs %
42.53%
Holding
111
New
24
Increased
21
Reduced
23
Closed
30
Top Buys
| 1 |
NovoCure
NVCR
|
$81.6M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$65.8M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$46.1M |
| 4 |
Integra LifeSciences
IART
|
$28.9M |
| 5 |
AstraZeneca
AZN
|
$26.8M |
Top Sells
| 1 |
Sanofi
SNY
|
$35.3M |
| 2 |
IDEAYA Biosciences
IDYA
|
$33.2M |
| 3 |
Revolution Medicines
RVMD
|
$22M |
| 4 |
10x Genomics
TXG
|
$21.5M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$15.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
NovoCure
NVCR
$1.38B
| $81.6M | 5.13% | +2,739,704 | New | +$81.6M |
|
2
TG Therapeutics
TGTX
$4.65B
| $80.7M | 5.07% | 2,681,242 +146,702 | +6% | +$4.42M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $65.8M | 4.14% | +1,001,400 | New | +$65.8M |
|
4
Krystal Biotech
KRYS
$4.27B
| $56.1M | 3.53% | 358,379 +141,400 | +65% | +$22.2M |
|
5
Grifois
GRFS
$6.78B
| $49.1M | 3.09% | 6,605,425 +2,083,722 | +46% | +$15.5M |
|
6
Axogen
AXGN
$743M
| $48.7M | 3.06% | 2,955,943 -50,000 | -2% | -$824K |
|
7
Iovance Biotherapeutics
IOVA
$807M
| $48.5M | 3.05% | 6,560,000 -1,968,500 | -23% | -$14.6M |
|
|
8
Teva Pharmaceuticals
TEVA
$21.1B
| $46.1M | 2.9% | +2,093,000 | New | +$46.1M |
|
9
Terns Pharmaceuticals
TERN
$609M
| $45.1M | 2.83% | 8,142,500 +1,918,956 | +31% | +$10.6M |
|
10
Organogenesis Holdings
ORGO
$653M
| $40M | 2.51% | 12,484,876 +645,000 | +5% | +$2.06M |
|
11
Nurix Therapeutics
NRIX
$714M
| $39.6M | 2.49% | 2,102,833 +1,036,999 | +97% | +$19.5M |
|
12
United Therapeutics
UTHR
$13.8B
| $38.6M | 2.43% | 109,394 +7,500 | +7% | +$2.65M |
|
13
Celcuity
CELC
$2.17B
| $33.6M | 2.11% | 2,565,087 +1,319,700 | +106% | +$17.3M |
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $32.9M | 2.07% | 2,492,000 +1,401,016 | +128% | +$18.5M |
|
15
Jasper Therapeutics
JSPR
$45.5M
| $32M | 2.01% | 1,494,420 +150,755 | +11% | +$3.22M |
|
|
16
Integra LifeSciences
IART
$1.18B
| $28.9M | 1.82% | +1,276,000 | New | +$28.9M |
|
17
Neuropace
NPCE
$303M
| $27.2M | 1.71% | 2,433,168 | – | – |
|
|
18
AstraZeneca
AZN
$248B
| $26.8M | 1.68% | +409,000 | New | +$26.8M |
|
19
C4 Therapeutics
CCCC
$185M
| $25.1M | 1.58% | 6,978,942 +374,946 | +6% | +$1.35M |
|
20
QuidelOrtho
QDEL
$1.95B
| $24.4M | 1.53% | 547,082 -138,918 | -20% | -$6.19M |
|
21
Insmed
INSM
$28.8B
| $22.1M | 1.39% | 320,272 +290,000 | +958% | +$20M |
|
22
Inhibikase Therapeutics
IKT
$134M
| $20.6M | 1.29% | +6,325,000 | New | +$20.6M |
|
23
Ascendis Pharma
ASND
$11.8B
| $19.8M | 1.25% | +144,000 | New | +$19.8M |
|
24
Rigel Pharmaceuticals
RIGL
$697M
| $19M | 1.2% | 1,130,679 +195,891 | +21% | +$3.29M |
|
25
Praxis Precision Medicines
PRAX
$958M
| $18.7M | 1.18% | 243,540 -15,858 | -6% | -$1.22M |
|